These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 25313709)
1. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity. Cheng HC; Lee SM; Hsieh YT; Lin PK Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709 [TBL] [Abstract][Full Text] [Related]
2. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Kim J; Kim SJ; Chang YS; Park WS Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184 [TBL] [Abstract][Full Text] [Related]
3. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589 [TBL] [Abstract][Full Text] [Related]
4. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921 [TBL] [Abstract][Full Text] [Related]
5. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis. Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024 [TBL] [Abstract][Full Text] [Related]
6. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498 [TBL] [Abstract][Full Text] [Related]
7. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867 [TBL] [Abstract][Full Text] [Related]
8. Reactivation of retinopathy of prematurity after bevacizumab injection. Hu J; Blair MP; Shapiro MJ; Lichtenstein SJ; Galasso JM; Kapur R Arch Ophthalmol; 2012 Aug; 130(8):1000-6. PubMed ID: 22491394 [TBL] [Abstract][Full Text] [Related]
9. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity. Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243 [TBL] [Abstract][Full Text] [Related]
10. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158 [TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity. Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D Retina; 2011; 31(7):1239-47. PubMed ID: 21555969 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity. Erol N; Gürsoy H; Sahin A; Basmak H J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Mintz-Hittner HA; Kuffel RR Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599 [TBL] [Abstract][Full Text] [Related]
16. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Kychenthal A; Dorta P Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192 [TBL] [Abstract][Full Text] [Related]
18. Reactivation of retinopathy of prematurity after ranibizumab treatment. Wong RK; Hubschman S; Tsui I Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252 [TBL] [Abstract][Full Text] [Related]
19. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results]. Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695 [TBL] [Abstract][Full Text] [Related]
20. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity. Sahinoglu-Keskek N; Akkoyun I; Torer B Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]